Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) CFO David Nassif sold 10,000 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $30.31, for a total transaction of $303,100.00. Following the transaction, the chief financial officer directly owned 120,300 shares in the company, valued at $3,646,293. This trade represents a 7.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Pharvaris Price Performance
PHVS stock opened at $29.47 on Thursday. The stock has a market capitalization of $1.93 billion, a PE ratio of -9.27 and a beta of -2.34. The company’s 50-day moving average is $28.66 and its 200-day moving average is $27.01. Pharvaris N.V. has a 1 year low of $15.46 and a 1 year high of $33.33.
Pharvaris (NASDAQ:PHVS – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. On average, analysts anticipate that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Report on Pharvaris
Pharvaris News Roundup
Here are the key news stories impacting Pharvaris this week:
- Positive Sentiment: Short interest in Pharvaris fell sharply in mid-May, dropping 42.9% to 600,645 shares. That lower bearish positioning can be viewed as a constructive signal for the stock. Article link
- Positive Sentiment: Brokerage coverage remains supportive, with Pharvaris receiving a consensus rating of “Moderate Buy,” which suggests analysts still see meaningful upside potential. Article link
- Neutral Sentiment: The company also continues to trade near the upper end of its 52-week range after beating first-quarter EPS estimates, which helps reinforce investor confidence in the name. Article link
- Negative Sentiment: Recent insider selling by CFO David Nassif, Director Viviane Monges, and insider Anna Nijdam may be pressuring sentiment, even though some of the sales were tied to tax withholding or equity vesting. Article link
Hedge Funds Weigh In On Pharvaris
Several hedge funds have recently modified their holdings of PHVS. GF Fund Management CO. LTD. bought a new position in shares of Pharvaris in the fourth quarter valued at approximately $35,000. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Pharvaris in the third quarter valued at approximately $75,000. Barclays PLC bought a new position in shares of Pharvaris in the fourth quarter valued at approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Pharvaris in the fourth quarter valued at approximately $86,000.
About Pharvaris
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Stories
- Five stocks we like better than Pharvaris
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
